We report on dermatomyositis-like adverse cutaneous reactions followin
g long-term maintenance therapy with hydroxyurea in two patients suffe
ring from chronic myelogenous leukaemia (CML). In addition to non-spec
ific side effects, such as xerosis, pruritus and hyperpigmentation, bo
th patients presented with more specific skin changes, i.e. erythemato
us lesions, scaling, and partially atrophic areas distributed in a lin
ear fashion on the dorsal aspects of the hands and fingers. In additio
n, teleangiectatic erythema of the face was present in both patients,
and this was associated with oedema of the eyelids in one patient. Des
pite these dermatomyositis-like features there were no clinical signs
of muscular involvement, and muscle-specific enzymes were within norma
l ranges. Skin biopsy specimens revealed an interface dermatitis chara
cterized by a lichenoid cell infiltrate, vacuolar alteration of basal
cells, necrotic keratinocytes within the spinous 2one, focal hypergran
ulosis, orthohyperkeratosis and telangiectases in the upper part of th
e dermis. Analogous histopathological findings have been documented in
lichen planus-like skin changes on the hands following hydroxyurea th
erapy. It seems doubtful whether there are actually any major differen
ces between those skin changes described as dermatomyositis-like and t
hose interpreted as lichen planus-like in patients receiving long-term
hydroxyurea therapy.